jRCT ロゴ

臨床研究等提出・公開システム

Top

Japanese

Jan. 29, 2019

July. 21, 2022

jRCT2080224535

-

JPCT@msd.com

-

JPCT@msd.com

completed

Feb. 15, 2019

1140

Interventional

treatment purpose

3

18age old over
No limit

Female

investigational material(s)
Generic name etc :
INN of investigational material : pembrolizumab, paclitaxel, doxorubicin hydrochloride, epirubicin, cyclophosphamide
Therapeutic category code : 42- Antineoplastic agents
Dosage and Administration for Investigational material :

control material(s)
Generic name etc :
INN of investigational material : paclitaxel, doxorubicin hydrochloride, epirubicin, cyclophosphamide
Therapeutic category code : 42- Antineoplastic agents
Dosage and Administration for Investigational material :

efficacy

safety
efficacy

-

-
approved

Aug. 22, 2018

NCT03725059
ClinicalTrials.gov
JapicCTI-194604
Japan/Asia except Japan/North America/Europe

History of Changes

No Publication date
3 July. 21, 2022 (this page) Changes
2 June. 02, 2022 Detail Changes
1 Feb. 06, 2019 Detail